SCHEDULE 13D: OrbiMed Entities Disclose 8.4% Stake in Sionna Therapeutics Following IPO

OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC have filed a Schedule 13D, revealing a beneficial ownership of 8.4% of Sionna Therapeutics, Inc.'s common stock, acquired through pre-IPO investments and participation in the initial public offering.

Summary

• OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC (the "Reporting Persons") collectively beneficially own 3,704,959 shares of Sionna Therapeutics, Inc. common stock, representing approximately 8.4% of the outstanding class.
• The shares are held by OrbiMed Private Investments VIII, L.P. ("OPI VIII"), with OrbiMed GP serving as its general partner and OrbiMed Advisors as the managing member of OrbiMed GP, granting them shared voting and dispositive power.
• The investment was made for general investment purposes, not with the intention of acquiring control of Sionna Therapeutics.
• OPI VIII acquired 2,560,951 shares of Series B convertible preferred stock in February 2022 and 2,048,760 shares of Series C convertible preferred stock in March 2024, both at $9.762 per share.
• Prior to Sionna's IPO, Series B and C preferred stock converted into common shares at a 1-for-1.4611 ratio.
• OPI VIII also purchased 550,000 common shares in the IPO at $18.00 per share.
• The source of funds for these purchases was the working capital of OPI VIII.
• Peter A. Thompson, a member of OrbiMed Advisors, serves on Sionna Therapeutics' Board of Directors, and is obligated to transfer any equity-based compensation received from Sionna to OrbiMed entities for OPI VIII.
• The Reporting Persons are party to a Third Amended and Restated Investors' Rights Agreement, granting them demand, piggyback, and Form S-3 registration rights for their shares.
• OPI VIII and Peter A. Thompson are subject to a lock-up agreement for 180 days following the IPO's final prospectus supplement, restricting the sale or transfer of shares.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of a significant ownership stake and related agreements, with no explicit positive or negative sentiment regarding the issuer's performance or outlook. It reflects a neutral, compliance-driven filing.

Positives

• Significant institutional investment from OrbiMed, a reputable healthcare-focused investment firm, signals confidence in Sionna Therapeutics.
• The investment was made for general investment purposes, indicating a long-term strategic interest rather than an immediate intent to control or disrupt the company.
• The Investors' Rights Agreement provides liquidity pathways for OrbiMed's substantial stake through various registration rights (S-1, piggyback, S-3), which could benefit other shareholders by facilitating future offerings.

Risks

• The Reporting Persons intend to review their investment periodically and may acquire or dispose of shares based on market conditions and the Issuer's performance, which could introduce volatility.
• The lock-up agreement restricts the sale of a significant block of shares for 180 days post-IPO, and the expiration of this period could lead to increased selling pressure if OrbiMed decides to divest.

Future Outlook

The Reporting Persons intend to continuously review their investment in Sionna Therapeutics based on various factors, including the Issuer's business, financial condition, and market conditions. They may acquire additional shares or dispose of existing shares in the future, either in the open market or through privately negotiated transactions, depending on their assessment of the investment's attractiveness.

Industry Context

This Schedule 13D filing is a standard disclosure for significant ownership stakes in publicly traded companies, particularly after an IPO. OrbiMed's investment in Sionna Therapeutics aligns with its focus on the healthcare and biotechnology sectors, indicating continued institutional interest and capital flow into innovative therapeutic companies.

Corporate Governance

Related Party Transactions

• Peter A. Thompson, a member of OrbiMed Advisors and a director of Sionna Therapeutics, is obligated to transfer any equity-based compensation received from Sionna to OrbiMed Advisors and GP VIII, who will then provide such benefits to OPI VIII.

Stakeholder Impact

• **Shareholders**: The disclosure of a significant institutional investor's stake provides transparency and may influence investor confidence. The lock-up agreement impacts the immediate liquidity of a large block of shares, while registration rights offer future liquidity potential.
• **Company Management**: The presence of an OrbiMed representative on the board (Peter A. Thompson) indicates a level of oversight and potential influence from a major investor.
• **Employees**: No direct impact mentioned, but the company's financial stability and strategic direction, influenced by major investors, can indirectly affect employees.

Next Steps

• The lock-up agreement for OPI VIII and Peter A. Thompson will expire 180 days after the date of the final prospectus supplement relating to the IPO, potentially allowing for sales of shares.
• The demand registration rights and short-form registration rights granted under the Investors' Rights Agreement will terminate on the fifth anniversary of the completion of the IPO.

Key Dates

Keywords

Sionna Therapeutics, OrbiMed Advisors, OrbiMed Capital, Schedule 13D, Beneficial Ownership, Common Stock, IPO, Preferred Stock Conversion, Investment Management, Registration Rights, Lock-Up Agreement, Biotechnology Investment, SEC Filing